Evidence map›Paper›PMID 32759243›Full record

Observational studyBMJ open2020

Real-world outcomes comparison among adults with atrial fibrillation undergoing catheter ablation with a contact force porous tip catheter versus a second-generation cryoballoon catheter: a retrospective analysis of multihospital US database.

Alexandru Costea, Laura Goldstein, Sonia Maccioni, Iftekhar Kalsekar, Rahul Khanna

Open access · goldAbstract readObservational Study
In one paragraph

Observational study in BMJ open, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.1field-weighted citation impact, top 47% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Alexandru CosteaDepartment of Internal Medicine, Center for Electrophysiology, Rhythm Disorders and Electro-Mechanical Interventions, University of Cincinnati, Cincinnati, Ohio, USA.
Laura GoldsteinFranchise Health Economics and Market Access, Johnson and Johnson Medical Devices, Irvine, California, USA.
Sonia MaccioniFranchise Health Economics and Market Access, Johnson and Johnson Medical Devices, Irvine, California, USA.
Iftekhar KalsekarMedical Device Epidemiology, Johnson and Johnson Medical Devices, New Brunswick, New Jersey, USA.
Rahul KhannaMedical Device Epidemiology, Johnson and Johnson Medical Devices, New Brunswick, New Jersey, USA rkhann14@its.jnj.com.ORCID 0000-0002-2478-1724
Johnson & Johnson (United States) · USUniversity of Cincinnati · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveTo compare real-world clinical and economic outcomes among atrial fibrillation (AF) patients undergoing cardiac ablation with the contact force-sensing porous tip THERMOCOOL SMARTTOUCH SF (STSF) catheter versus the Arctic Front Advance Cryoballoon (AFA-CB) catheter.

designRetrospective, observational cohort study.

settingPremier Healthcare Database (PHD), between 1 September 2016 and 30 June 2018.

participantsPatients with AF (≥18 years) were included if they had an index ablation procedure performed using the STSF catheter or AFA-CB catheter at a US hospital that consistently provided inpatient and outpatient data to PHD in the 12-month preindex period. Using 1:1 propensity score matching, patient groups were matched on study covariates. PRIMARY AND SECONDARY OUTCOME MEASURES: Cost, length of stay (LOS), readmissions, direct current cardioversion (DCCV) and reablation outcomes were compared between matched cohorts of STSF and AFA-CB patients.

resultsA total of 3015 patients with AF met the study criteria, of which 1720 had ablation using the STSF catheter and 1295 had ablation using the AFA-CB catheter. In the propensity-matched sample, patients receiving ablation with the STSF catheter had ~17% lower total costs (US$23 096 vs US$27 682, p≤0.0001) and ~27% lower supply costs (US$10 208 vs US$13 816, p≤0.0001) versus patients receiving ablation with the AFA-CB catheter. A significantly lower likelihood of 4-month to 6-month cardiovascular-related readmission (OR 0.460, 95% CI 0.220 to 0.959) was associated with the STSF catheter versus the AFA-CB catheter. No significant differences in LOS, room and board cost, 4-month to 6-month all-cause and AF-related readmissions, DCCV and reablation were observed among technologies. Sensitivity analysis restricting patient sample by provider ablation volume demonstrated similar results.

conclusionLower index ablation total and supply costs were observed among patients with AF undergoing cardiac catheter ablation using the STSF catheter versus the AFA-CB catheter.

Indexed as

Atrial FibrillationCatheter AblationAdultCathetersEquipment DesignHumansPorosityRetrospective StudiesTreatment Outcomecardiac epidemiologycoronary interventionepidemiologypacing & electrophysiology

Identifiers

PMID32759243
PMCPMC7409957
OpenAlexW3047438381

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.